0001209191-17-005347.txt : 20170124
0001209191-17-005347.hdr.sgml : 20170124
20170124175121
ACCESSION NUMBER: 0001209191-17-005347
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170120
FILED AS OF DATE: 20170124
DATE AS OF CHANGE: 20170124
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PUMA BIOTECHNOLOGY, INC.
CENTRAL INDEX KEY: 0001401667
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770683487
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10880 WILSHIRE BLVD.
STREET 2: SUITE 2150
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
BUSINESS PHONE: (424) 248-6500
MAIL ADDRESS:
STREET 1: 10880 WILSHIRE BLVD.
STREET 2: SUITE 2150
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
FORMER COMPANY:
FORMER CONFORMED NAME: INNOVATIVE ACQUISITIONS CORP
DATE OF NAME CHANGE: 20070601
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BRYCE RICHARD PAUL
CENTRAL INDEX KEY: 0001553037
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35703
FILM NUMBER: 17544652
MAIL ADDRESS:
STREET 1: C/O PUMA BIOTECHNOLOGY, INC.
STREET 2: 10880 WILSHIRE BOULEVARD, SUITE 2150
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-01-20
0
0001401667
PUMA BIOTECHNOLOGY, INC.
PBYI
0001553037
BRYCE RICHARD PAUL
C/O PUMA BIOTECHNOLOGY, INC.
10880 WILSHIRE BLVD., SUITE 2150
LOS ANGELES
CA
90024
0
1
0
0
SR VP, CLINICAL RESEARCH & DEV
COMMON STOCK
2017-01-20
4
S
0
2293
33.2351
D
29237
D
The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 19, 2016 to satisfy tax obligations in connection with the vesting of restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.90 to $33.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
/s/ Richard Paul Bryce
2017-01-24